'Pharma Clinical Trial Services Market Will Reach $30.6 Billion in 2015' Predicts New Visiongain Report

LONDON, February 1, 2013 /PRNewswire/ --

A new report by Visiongain predicts that the world market for pharma clinical trial services will be worth $30.6bn in 2015. Between 2011 and 2017, the global market will grow with a high single digit CAGR. Demand for late phase trial services will drive growth to 2023. Those findings appear in Pharma Clinical Trial Services: World Market 2013-2023, published in January 2013.

Throughout the 10-year forecast period, late-stage trials will account for the greatest proportion of revenues for clinical research organisations (CROs). In the first half of the forecast period, lifecycle management strategies, demands from regulators for post-marketing safety studies and pharma co economic data will drive growth in that industry.

Richard Lang, a pharmaceutical industry analyst for visiongain, said: "In the last decade, demand for outsourced clinical trial services grew rapidly as pharma pipelines grew and trials became increasingly large and complex. Drug developers built up large, complex networks of service providers, which they are now seeking to simplify. They are looking to form strategic partnerships with a select few CROs covering long-term development projects.

"CROs must expand to offer a one-stop shop for pharmaceutical clients in order to take advantage of these strategic partnerships. They will look to new technology, including e-clinical tools, to improve their service offerings, as well as expanding into emerging markets. Many leading CROs established bases in BRIC nations in the last decade. In this decade, growth for these CROs will be focused on building upon the service portfolio in these markets, as well as entering new emerging markets in Asia, Latin America and Central and Eastern Europe."

Opportunities for growth in this decade for small CROs will stem from specialisation. Demand for biomarker validation services offers one potential niche area in which all larger CROs have yet to invest heavily. Therapeutic specialisation offers another opportunity to these companies. Cancer, cardiovascular diseases and CNS disorders accounted for more than half of clinical trial service revenues in 2011. Strong growth is expected in all three sectors of the market in this decade, driven by rising disease incidence and unmet treatment needs. There were close to 1,000 cancer drugs in clinical development in 2012, with many more in pre-clinical development.

The new study forecasts the leading national pharma clinical trials service markets. In 2011, the US and Western Europe dominated the market, accounting for more than three quarters of global revenues. During this decade, however, pharmaceutical clients will increasingly demand trial services in emerging countries. Lower costs and large treatment-naïve patient populations will drive this demand, as will access to rapidly emerging pharmaceutical markets. The market share for the BRIC nations (Brazil, Russia, India and China) will triple during the period 2011-2023. The US will continue to be the largest market for clinical trial services throughout the decade however.

Pharma Clinical Trial Services: World Market 2013-2023 provides quantitative and qualitative analysis of the clinical trial services market. It shows revenue forecasts for world-level submarkets and national markets. Also, it identifies future trends that will affect market players. The study adds to Visiongain's portfolio of analytical reports covering the pharmaceutical outsourcing and service markets.

For further information concerning the Visiongain's Pharma Clinical Trial Services: World Market 2013-2023 report please visit: http://www.visiongain.com/Report/973/Pharma-Clinical-Trial-Services-World-Market-2013-2023

Contact:
Email:  Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

Companies Listed

3C Alliance
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agility Clinical
Allscripts
Amgen
Aptuit
ASAN Medical Center
Associação Brasileira de CROs (Abracro)
Association for the Accreditation of Human Research Protection Programs (AAHRPP)
Association of Clinical Trial Organisations (ACTO) [Russia]
Astellas Pharma
Avista Capital Partners
Bayer
BeijingWits Medical Consulting (part of ICON)
Berry Consultants
BioClinica
BioDuro (part of PPD)
BioDuro Biologics
BioTrak
BML
Boehringer Ingelheim
Bristol-Myers Squibb
Caprion Proteomics
Catalent
Center for Biologics Evaluation and Research (CBER) [US]
CenterWatch
Central Drugs Standard Control Organization (CDSCO) [India]
Charles River Laboratories
Chinese Ministry of Commerce
Clinical Trial Support
Clinigene International
Clinipace Worldwide
ClinStar
CMIC
CMIC (Beijing) Co
CNS Healthcare
CNS Vital Signs
Cogtest (part of The Cognition Group)
Corex Pharmaceutical
Council for International Organizations of Medical Sciences (CIOMS)
Cromos Pharma
Czura Thornton
Dako (part of Agilent Technologies)
Department of Health [UK]
Drug Controller General of India (DCGI)
Eisai
Ekam Imaging
Eli Lilly
European Commission
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Parliament
Firecrest Clinical (part of ICON)
Food and Drug Administration (US FDA)
GCP ClinPlus
GE Healthcare
Genstar Capital
Global CNS Research
Global Research Services (GRS)
GSK
Hellman & Friedman
i3 Research (part of inVentiv Health)
ICON
INC Research
Infociencia (part of RPS)
Innovative Medicines Initiative (IMI)
Inspire
Institute for Medical Research Management and Biometrics (IMEREM, part of RPS)
Integrium
International Cancer Genome Consortium
International Conference of Harmonisation (ICH)
inVentiv Health
J&J
Japan Pharmaceutical Manufacturers Association (JPMA)
Java Clinical
Julphar
Kendle (part of INC Research)
Kforce
Kforce Clinical Research (KCR, part of inVentiv Health)
Kinship Technologies (part of PRA)
Korea Drug Development Fund (KDDF)
Korea Food and Drug Administration (KFDA)
Korea National Enterprise for Clinical Trials (KoNECT)
Kun Tuo (part of Quintiles)
LSK Global
MAB Discovery
Malaysian Biotechnology Corporation
Maximax Pharmaceutical Research
MDS Pharma Services (part of INC Research)
MedAvante
Medelis
Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
Medidata Solutions
Medipal Holdings
Medivation
Merck & Co.
Merck KGaA
Metabolon
MetricStream
Ministry of Health, Labor and Welfare (MHLW, Japan)
Molecular Neuroimaging
Myriad Genetics
National Cancer Institute (NCI) [US]
National Taiwan University Hospital (NTUH)
Nautic Partners
Neuroimage
NextGen Sciences
Nexus Oncology
NHS Research Scotland (NRS)
OCT
Omnicare
Ontario Teachers' Pension Plan
Oxford Cancer Biomarkers
Oxford Gene Technology (OGT)
Oxford Outcomes (part of ICON)
Pacific Biomarkers
Paragon Biomedical (part of Clinipace Worldwide)
Paramax International (part of RPS)
Parexel International
Perceptive Informatics (part of Parexel)
PFC Pharma Focus (part of Clinipace Worldwide)
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
PharmaNet Development Group (part of inVentiv Health)
PPD
PRA International
Prana Biotechnology
PriceSpective (part of ICON)
Prodia Clinical Laboratory
Proteome Sciences
ProTrials Research
Psychmed (part of The Cognition Group)
QED Clinical Services
Quintiles
Regulus Pharmaceutical Consulting (part of Clinipace Worldwide)
ReSearch Pharmaceutical Services (RPS)
Rules Based Medicine (now Myriad RBM, part of Myriad Genetics)
Samsung
SAS
Shanghai Clinical Research Center
ShangPharma
Shire
State Food and Drug Administration (SFDA) [China]
Sugi Medical Co (part of CMIC)
Taijitu Biologics
Tessella
The Carlyle Group
The Cognition Group
Theorem Clinical Research
Theradex Systems
Therapeutic Goods Administration (TGA) [Australia]
Therapharm Recherches (part of RPS)
Thomas H. Lee Partners
Tigermed Consulting
Timaq Medical Imaging (part of ICON)
Trident Clinical Research (part of INC Research)
UCB
Veeda Clinical Research
Vigiun (part of Chiltern International)
VirtualScopics
Warburg Pincus
West Coast Clinical Trials (WCCT)
World Health Organization (WHO)
Worldwide Clinical Research
WuXi AppTec
WuXi PharmaTech 

Notes for Editors

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zones focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100